Eikon Therapeutics, Inc. (EIKN) · Oct 26, 2026 · Other events
Updated Phase 2 data — 63.1% ORR / 89.2% DCR; squamous DOR 12.9 months
Eikon Therapeutics’ EIK1001 clinical update confirms durable NSCLC activity and outpatient dosing, but largely extends a signal already shown at ASCO.
Eikon is a late-stage oncology biotech moving EIK1001 from a Phase 2 efficacy signal into the registrational TeLuRide-008 study, alongside a separate registrational melanoma program. The company had already told investors that a comprehensive TeLuRide-005 update was scheduled for ESMO, while its ASCO dataset showed a 61% pooled response rate and 90.8% disease-control rate.
The clinical signal held up with longer follow-up, but did not materially improve. The filing reports pooled efficacy of 63.1% ORR and 89.2% DCR after 17.2 months of median follow-up, versus the earlier ASCO readout’s 61% ORR and 90.8% DCR. The squamous cohort remains the strongest piece: 72.4% ORR, 100% DCR and a 12.9-month median duration of response. 〔0〕
| Metric | Updated filing | Earlier public readout |
|---|---|---|
| Pooled ORR | 63.1% (Efficacy Update) | 61% (ASCO readout) |
| Pooled DCR | 89.2% (Efficacy Update) | 90.8% (ASCO readout) |
| Squamous ORR | 72.4% (Efficacy Update) | 72.4% (ASCO readout) |
| Squamous DCR | 100% (Efficacy Update) | 100% (ASCO readout) |
| Squamous median DOR | 12.9 months (Efficacy Update) | Not yet mature (ASCO readout) |
| Grade 3+ TRAEs | 48.6% (Safety Update) | 48.6% (ASCO readout) |
| TRAEs causing discontinuation | 6.9% (Safety Update) | Not highlighted previously |
Durability and usability are the incremental positives. The squamous response duration is now mature enough to provide a clearer proof point, while the safety update continues to support outpatient administration: Grade 3 or higher treatment-related adverse events occurred in 48.6% of participants, discontinuations were 6.9%, cytokine-release syndrome was limited to Grade 1 or 2, and no treatment-related adverse event caused death. 〔1〕
The main limitation is that this remains an uncontrolled, company-sponsored Phase 2 signal layered onto standard treatment. The filing adds no randomized comparison, overall-survival result, or registrational efficacy readout. TeLuRide-008 is active, but its first interim analysis is not expected until the second half of 2027; the study is designed to select the dose for the remainder of the Phase 2/3 program.
Bottom line: This update validates EIK1001’s earlier NSCLC signal and improves confidence in durability and outpatient delivery, but it is confirmation rather than a step-change. The business story advances mainly because the registrational program remains supported, not because the data reset expectations.
TeLuRide-008 interim dose-selection analysis, second half of 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!